Figures & data
Table 1 Demographic and baseline clinical characteristics
Table 2 Summary of efficacy results for the only patient who tested positive for both IgG and neutralizing antibodies
Figure 1 Heart rate variability as assessed by SDNN: individual values at baseline and at 55 weeks.
![Figure 1 Heart rate variability as assessed by SDNN: individual values at baseline and at 55 weeks.](/cms/asset/9b3b3b39-1b5d-4340-aca7-19ff679b037c/dddt_a_12165951_f0001_c.jpg)
Figure 2 LVMI over time for the patient who had LVH at baseline.
Abbreviations: LVH, left ventricular hypertrophy; LVMI, left ventricular mass index.
![Figure 2 LVMI over time for the patient who had LVH at baseline.](/cms/asset/6f147eff-5f9e-4b63-97e5-715af071a556/dddt_a_12165951_f0002_c.jpg)
Figure 3 Correlation between change from baseline to week 55 in SDNN and LVMI in patients with baseline SDNN <100 ms.
Abbreviation: LVMI, left ventricular mass index.
![Figure 3 Correlation between change from baseline to week 55 in SDNN and LVMI in patients with baseline SDNN <100 ms.](/cms/asset/5d9be31b-1ced-48ac-8c4d-ad83b2aff5b6/dddt_a_12165951_f0003_c.jpg)
Figure 4 Mean (SE) change from baseline in eGFR.
Abbreviations: eGFR, estimated glomerular filtration rate; SE, standard error; SP, safety population.
![Figure 4 Mean (SE) change from baseline in eGFR.](/cms/asset/8af5788b-1632-4b94-8d71-369297abd564/dddt_a_12165951_f0004_c.jpg)
Figure 5 Mean plasma Gb3 over time for the overall population and by sex.
Abbreviation: Gb3, globotriaosylceramide.
![Figure 5 Mean plasma Gb3 over time for the overall population and by sex.](/cms/asset/93494898-646e-496a-aabe-f7631794656d/dddt_a_12165951_f0005_c.jpg)